Biopharmx Corp (NYSEAMERICAN:BPMX) shares gapped up before the market opened on Friday . The stock had previously closed at $0.61, but opened at $0.63. Biopharmx shares last traded at $0.83, with a volume of 10,136,711 shares changing hands.
Separately, Maxim Group reaffirmed a “buy” rating and set a $1.00 price objective on shares of Biopharmx in a research note on Friday, December 13th.
The company’s 50 day simple moving average is $0.35.
Biopharmx (NYSEAMERICAN:BPMX) last posted its quarterly earnings data on Tuesday, December 10th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.08.
An institutional investor recently bought a new position in Biopharmx stock. Barclays PLC purchased a new position in Biopharmx Corp (NYSEAMERICAN:BPMX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 175,000 shares of the biotechnology company’s stock, valued at approximately $58,000. Barclays PLC owned about 1.23% of Biopharmx at the end of the most recent quarter.
Biopharmx Company Profile (NYSEAMERICAN:BPMX)
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Read More: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.